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ABSTRACT: The monofunctional platinum drug phenan-
thriplatin (phenPt) blocks the replication of cancer cells 
even if it reacts with only one guanine base. However, 
there is still insufficient experimental data to improve its 
cytotoxicity and all previously proposed chemical modi-
fications of the parent structure have resulted in a loss of 
activity. We use theoretical tools to illustrate the key steps 
in the biological mechanisms of phenPt—that is, its acti-
vation in water and subsequent attack on DNA. Our sim-
ulations suggest that the measured kinetic parameters, 
which are based on free nucleobases in solution, need to 
be reinterpreted because a self-assembled stacked reac-
tive adduct is formed that is inaccessible in real DNA. 
The constants reported here will help guide future work 
in the synthesis of anticancer platinum drugs. 
It was previously thought that only bifunctional plati-
num drugs, such as cisplatin [cisPt, cis-Pt(NH3)2Cl2], are 
of use in cancer chemotherapy,1 despite the fact that the 
efficacy of cisPt is limited by its severe side-effects and 
tumors may develop resistance during the first few 
months of treatment.2 Promising progress into the design 
of better cancer drugs has recently been made by Lippard 
and coworkers,3 who synthesized phenanthriplatin 
[phenPt, Pt(NH3)2(phenanthridine)Cl+]. This molecule is 
active against 60 human cancer cell lines and has a higher 
cytotoxicity than cisPt.3 Figure 1 shows that cisPt-like 
drugs attack two DNA bases, inducing a severe distortion 
in the double-stranded structure, whereas phenPt is a 
monofunctional platinum drug and reacts with only one 
base.4 The DNA architecture is therefore initially retained 
after treatment with phenPt. The attached metallo-drug 
later twists the single strand of the DNA template at the 
replication stage, which switches on the cell suicide pro-
gram.5 Non-targeted biomolecules (e.g., proteins rich in 
cysteine) are also damaged by both types of drug, which 
not only causes early inactivation, but also favors the de-
velopment of resistance to treatment.6 
The chemical reactions shown in Figure 1 need to be 
characterized before this novel phenPt-based metallo-
drug can be used clinically. The formation of covalent ad-
ducts of phenPt with isolated guanine and adenine moie-
ties has previously been studied to determine the equilib-
rium and rate constants.7 These experiments suggested 
that the induced lesions are kinetically controlled, alt-
hough it is unclear whether these results can be directly 
extrapolated to in vivo conditions. To help to resolve this 
key question, we assessed the reactivity of phenPt using 
density functional theory (DFT) calculations, a computa-
tional approach widely exploited in studying the reactiv-
ity of bifunctional metallo-drugs,8–12 but rarely used for 
monofunctional drugs such as phenPt.13 Our conclusions 
are based on B3LYP-D3 calculations implemented in 
Gaussian 16.14,15 All the quantum mechanical details are 
given in the Supporting Information (SI). 
 
 
Figure 1. Schematic representation of the biological action 
of the cisplatin (cisPt) and phenanthriplatin (phenPt) 
metallo-drugs. From top to bottom: activation by hydrolysis; 
targeted reaction with DNA (modeled as 9-methyladenine 
and 9-methylguanine); and reaction with a cysteine (cys) 
residue present in proteins. The main products are associated 
with the attack on the N7 position in guanine (blue arrows) 
and to the sulfur in cysteine (red arrows), which lead to DNA 
adducts and an attack on proteins, respectively. 
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 The initial step in the computational strategy is to fully 
optimize all the species involved in the reaction, includ-
ing the reagents (R), the reactive adducts (RA), the tran-
sition states (TS), the product adducts (PA) and the sepa-
rated products (P). These structures correspond to the 
critical points in the energetic profile of the reaction (see 
SI). Although experiments did not capture all these spe-
cies, X-ray data are available for the isolated drug and the 
final products of the reaction with adenine and guanine 
and these data were used to validate our methodology.5,16 
phenPt can present as two isomers. Both forms were con-
sidered in this work, although all the values reported here 
are from isomer-M because we observed only a very 
small impact of the stereoisomers on the reactivity. Fur-
ther details about the structure of these isomers are given 
in the SI and in ref. 16. The minimum energy structures 
perfectly match the deposited experimental structures7 
with a deviation of c. 0.03 Å and 3° for the bond lengths 
and angles, respectively. The agreement between the the-
oretical (Table S1) and experimental geometries confirms 
the reliability of our strategy and ensures the quality of 
the delivered predictions. 
The reaction profile of phenPt corresponds to a mech-
anism starting with the hydrolysis of the leaving groups 
(chloride ligands marked in green at the top of Figure 1). 
Our calculations show that one water molecule enters the 
metal coordination sphere in similar way in both phenPt 
and cisPt. The incoming water molecule establishes a hy-
drogen bond with the ammonia ligand and a non-covalent 
bond that reorients the reactive atoms in the RA. This ad-
duct subsequently yields to the rupture of the bond be-
tween platinum and the chloride ligand and the simulta-
neous formation of a metal–water bond (all structures 
given in the SI). The penta-coordinated nature of the TS 
is monitored by the single-imaginary vibrational mode, 
which corresponds to the bond formation/breaking pro-
cess (Figure S2 and Table S7). The computed activation 
Gibbs free energy barrier and rate constant in Figure 2 
(∆G‡=24.2 kcal mol−1 and k = 1.1 × 10−5 s−1) are con-
sistent with the experimentally recorded values.7 To ex-
tract a biological conclusion from these results, we need 
to compare the numerical outcome with the activation of 
cisPt, which remains the gold standard for cancer treat-
ment. The calculations for cisPt (∆G‡ = 24.0 kcal mol−1 
and k = 1.6 × 10−5 s−1) are consistent with the literature 
value17–20 and we therefore conclude that the presence of 
a phenanthridine ring does not alter the kinetics of the hy-
drolysis/activation step. 
We assessed the critical step in the biological activity of 
cisPt and phenPt: the attack of the water-activated drugs 
on DNA. For consistency with previous work,7 the reac-
tions were modeled with 9-methylguanine (at the N7 po-
sition) and 9-methyladenine (at the N1 and N7 positions). 
The energies are shown in Figure 2 and more details are 
presented in Figures S3 and S4. The water–phenPt com-
plex interacts differently with the DNA purine bases. The 
reaction with guanine leads to a direct exchange of the 
inserted water molecule at the N7 position of the guanine. 
By contrast, the attack on the adenine base involves the 
transfer of a proton from the coordinated water molecule 
to the N7 position of the DNA base, an equilibrium pre-
viously reported for adenine, but not observed in gua-
nine.21,22 The proton transfer and the water à N7 equilib-
ria increase the partial charge of the adenine moiety when 
the RA is formed. As a consequence, the reaction of 
phenPt at the N7 guanine position (∆G‡=15.2 kcal mol−1 
and k = 4.4 × 101 s−1) is preferred to the damage of ade-
nine at either the N7 (∆G‡=17.1 kcal mol−1 and k = 1.8 × 
100 s−1) or N1 (∆G‡=19.1 kcal mol−1 and k = 6.2 × 10−2 
s−1) sites. The N7 adduct of both guanine and adenine 
leads to the most stable platination products, although the 
guanine product is kinetically favored. The stability of the 
induced damage by phenPt (∆G = −4.2 kcal mol−1 and 
Keq = 1.2 × 103) and cisPt (∆G = −4.7 kcal mol−1 and Keq 
= 2.8 × 103) drugs are similar. 
 
 
Figure 2. Free energy profiles for the reactions of phenPt 
(upper panel) and cisPt (lower panel): activation by hydrol-
ysis (green); reaction at the N7 (orange) and N1 (pink) posi-
tions of 9-methyladenine; attack at the N7 position of the 9-
methylguanine (blue); and reaction with a cysteine (red). 
The alternative mechanism for phenPt via the self-assem-
bled reactive adduct is indicated by dashed lines. The same 
energy scale is used in both panels. 
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Figure 3. Reactive adducts (RA) during the attack of 
phenPt on the N7 guanine site. The stacked RA is compati-
ble with the measured kinetics in free solution (upper panel), 
while the non-stacked form is the only structure possible in 
the reaction with DNA (lower panel). H-bonds are plotted as 
dashed yellow lines and π–π stacking is shown as a green 
surface. Color scheme: gray, C atoms; blue, N atoms; red, O 
atoms; purple, Pt atoms; white, H atoms. 
 
Our theoretical values correctly reproduce the attack on 
DNA by cisPt and the observed reaction trend of phenPt 
in the experiments (N7–guanine > N7–adenine > N1–ad-
enine). However, the calculations with phenPt yield ki-
netic parameters that are several orders of magnitude 
larger than the reported values.7 Earlier experiments have 
shown that phenPt preferentially reacts at the N7 position 
of guanine with slow kinetics (∆G‡ = 23.5 kcal mol−1 and 
k = 3.6 × 10−5 s−1). We therefore predict more rapid kinet-
ics for phenPt than cisPt (∆G‡ = 17.8 kcal mol−1 and k = 
5.5 × 10−1 s−1). Because good experimental/theoretical 
agreement was obtained at the hydrolysis stage, it is more 
likely that such a conflicting result arises from an incon-
sistency in the chemical model than from an error in the 
theory. 
Figure 1 shows that phenPt binds covalently to a single 
guanine base. The phenanthridine ring is oriented out-
wards from the double helix and is not intercalated be-
tween two base pairs —that is, phenPt does not interact 
with the base pairs during the platination of DNA (see 
Figure S7 and ref. 5). However, if the reaction is designed 
using isolated bases, as in the high-performance liquid 
chromatography experiments from which the rate con-
stants were obtained,7 phenPt can be assembled with 
guanine prior to attack by the metal. To confirm this hy-
pothesis, the reaction was simulated by repositioning the 
bases opposite to the phenanthridine ring. Figure 3 shows 
that phenanthridine anchors the guanine base via π−π 
stacking in the stacked RA, an interaction that is missing 
in the non-stacked RA. This additional contact can be 
seen as a green surface by computing the electron density 
and reduced density gradient as implemented in the 
NCIPlot code.23,24 The attack at the N7 position in gua-
nine through a self-assembled reactant has to overcome 
an energy barrier 7 kcal mol−1 higher than in the non-
stacked forms. The predicted activation energy is plotted 
in Figure 2 as dashed lines (∆G‡ = 20.3 kcal mol−1 and k 
= 8.0 × 10−3 s−1) and allows the experimental and theoret-
ical results to be reconciled. The same effect is observed 
in the attack on adenine, with an increase of c. 5 kcal 
mol−1. It should be stressed that the rate constant is very 
sensitive and a difference of 1 kcal mol−1 in the energetic 
barrier corresponds to one order of magnitude on the k-
scale. Our computational strategy is therefore at the limit 
of chemical accuracy (with a difference of only 3 kcal 
mol−1) if the reaction is modeled with self-assembled RA 
structures.25 More refined predictions can be produced us-
ing larger DNA fragments (e.g., a dodecamer structure), 
which will require the application of more elaborate com-
putational approaches, such as quantum mechanics/mo-
lecular mechanics calculations.26,27 However, the use of 
isolated base pairs within the DFT framework is sufficient 
to provide convergence with the experiments and to pre-
dict reliable kinetic parameters. 
The possible attack on sulfur-containing biomolecules 
was finally assessed by analyzing the reaction of the wa-
ter-activated drug to a cysteine moiety. The reaction with 
proteins rich in this amino acid is a source of the non-
targeted effects of these anticancer drugs, so the platina-
tion of cysteine provides a first model to predict unwanted 
reactions in healthy tissues.28 The optimized structures 
and reaction energy profiles (see SI) showed similar ki-
netics for the reactions of cisPt (∆G‡ = 20.9 kcal mol−1 
and k = 2.9 × 10−3 s−1) and phenPt (∆G‡ =19.0 kcal mol−1 
and k = 7.2 × 10−2 s−1). The damage inflicted on proteins 
appears to be thermodynamically rather than kinetically 
controlled. cisPt (∆G = −6.6 kcal mol−1 and Keq = 7.8 × 
104) produces more stable damage at cysteine than 
phenPt (∆G = 2.7 kcal mol−1 and Keq = 1.1 × 10−2). This 
mitigation of the attack on proteins confirms an additional 
advantage of monofunctional platinum drugs over classi-
cal bifunctional drugs.29 
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 Our results outline the biological mechanisms of 
phenPt, one of the most promising monofunctional plat-
inum drugs. The simulations are fully consistent with the 
available experimental data, with the key exception of the 
kinetics associated with the attack on the DNA bases. In 
contrast with the results obtained in solution, our calcula-
tions suggest that the attack of phenPt on DNA is even 
faster than that of cisPt and that hydrolysis is the rate-
limiting step in both reactions. The source of this incon-
sistency may be explained by stacking of the phenanthri-
dine ring that assembles the phenPt and bases prior to the 
platination reaction. The stacked reactant in Figure 3, 
which is accessible in free solution but inaccessible in the 
double helix, slows the kinetics down by several orders of 
magnitude. 
Although monofunctional drugs may improve the re-
sponse of patients to chemotherapy, attempts to optimize 
the parent phenPt molecule have so far been unsuccess-
ful. We hope that this report of self-assembled reactants 
will provide experimentalists with new lines of investiga-
tion in the design of improved anticancer drugs. 
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